Before taking Enasidenib(Avatrombopag)

Important safety information.

Warnings and Precautions

The most significant warning involves thrombotic and thromboembolic complications. DOPTELET should not be used to normalize platelet counts. Platelet counts require regular monitoring before, during, and after treatment to guide dosing and avoid excessive increases. Concomitant use with moderate or strong dual inhibitors or inducers of CYP2C9 and CYP3A4 enzymes requires dosage adjustments. Use during pregnancy may cause fetal harm, and breastfeeding is not recommended during treatment and for two weeks after the last dose.